Literature DB >> 15557191

Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling.

Naoki Hyakushima1, Hiroaki Mitsuzawa, Chiaki Nishitani, Hitomi Sano, Koji Kuronuma, Masanori Konishi, Tetsuo Himi, Kensuke Miyake, Yoshio Kuroki.   

Abstract

TLRs have been implicated in recognition of pathogen-associated molecular patterns. TLR4 is a signaling receptor for LPS, but requires MD-2 to respond efficiently to LPS. The purposes of this study were to examine the interactions of the extracellular TLR4 domain with MD-2 and LPS. We generated soluble forms of rTLR4 (sTLR4) and TLR2 (sTLR2) lacking the putative intracellular and transmembrane domains. sTLR4 consisted of Glu(24)-Lys(631). MD-2 bound to sTLR4, but not to sTLR2 or soluble CD14. BIAcore analysis demonstrated the direct binding of sTLR4 to MD-2 with a dissociation constant of K(D) = 6.29 x 10(-8) M. LPS-conjugated beads precipitated MD-2, but not sTLR4. However, LPS beads coprecipitated sTLR4 and MD-2 when both proteins were coincubated. The addition of sTLR4 to the medium containing the MD-2 protein significantly attenuated LPS-induced NF-kappaB activation and IL-8 secretion in wild-type TLR4-expressing cells. These results indicate that the extracellular TLR4 domain-MD-2 complex is capable of binding LPS, and that the extracellular TLR4 domain consisting of Glu(24)-Lys(631) enables MD-2 binding and LPS recognition to TLR4. In addition, the use of sTLR4 may lead to a new therapeutic strategy for dampening endotoxin-induced inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557191     DOI: 10.4049/jimmunol.173.11.6949

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells.

Authors:  S L Zunt; L V Burton; L I Goldblatt; E E Dobbins; M Srinivasan
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

2.  Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2.

Authors:  Koji Kuronuma; Hiroaki Mitsuzawa; Katsuyuki Takeda; Chiaki Nishitani; Edward D Chan; Yoshio Kuroki; Mari Nakamura; Dennis R Voelker
Journal:  J Biol Chem       Date:  2009-07-07       Impact factor: 5.157

3.  From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins.

Authors:  Mari L DeMarco; Robert J Woods
Journal:  Mol Immunol       Date:  2011-09-16       Impact factor: 4.407

4.  Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.

Authors:  Vishal Jain; Annett Halle; Kristen A Halmen; Egil Lien; Marie Charrel-Dennis; Sanjay Ram; Douglas T Golenbock; Alberto Visintin
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

5.  Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.

Authors:  Arunan S Vamadevan; Masayuki Fukata; Elizabeth T Arnold; Lisa S Thomas; David Hsu; Maria T Abreu
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

6.  Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes.

Authors:  Melanie J Scott; Timothy R Billiar
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

7.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

8.  Lipopolysaccharide-trap-Fc, a multifunctional agent to battle gram-negative bacteria.

Authors:  Philipp Gross; Katharina Brandl; Christine Dierkes; Jürgen Schölmerich; Bernd Salzberger; Thomas Glück; Werner Falk
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

9.  Toll-like receptor 4 (TLR4) and typhoid fever in Vietnam.

Authors:  Thi Hue Nguyen; Ngoc Lanh Mai; Thi Phuong Le; Vinh Ha; Tran Chinh Nguyen; Tinh Hien Tran; T Hieu Nguyen; Jeremy J Farrar; Sarah J Dunstan
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

10.  Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis.

Authors:  Keehoon Jung; Jung-Eun Lee; Hak-Zoo Kim; Ho Min Kim; Beom Seok Park; Seong-Ik Hwang; Jie-Oh Lee; Sun Chang Kim; Gou Young Koh
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.